Skip to main content
logo
Galderma Group AG (GDERF)
OTCMKTS · Delayed Price · Currency is USD
204.40
+11.82 (6.14%)
At close: Mar 10, 2026

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Neuromodulators Revenue
1.47B1.29B
Neuromodulators Revenue Growth
14.47%10.60%
Fillers & Biostimulators Revenue
1.10B1.01B
Fillers & Biostimulators Revenue Growth
8.58%4.97%
Injectable Aesthetics Revenue
2.57B2.30B
Injectable Aesthetics Revenue Growth
11.88%8.04%
Dermatological Skincare Revenue
1.45B1.33B
Dermatological Skincare Revenue Growth
8.87%9.82%
Therapeutic Dermatology Revenue
1.19B780.00M
Therapeutic Dermatology Revenue Growth
51.92%5.16%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
USA Revenue
2.23B1.81B
USA Revenue Growth
23.26%-0.03%
International Revenue
2.98B2.60B
International Revenue Growth
14.46%14.48%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Neuromodulators Constant Currency Growth
14.30%11.80%
Fillers & Biostimulators Constant Currency Growth
8.00%7.00%
Injectable Aesthetics Constant Currency Growth
11.50%9.60%
Dermatological Skincare Constant Currency Growth
9.30%10.70%
Therapeutic Dermatology Constant Currency Growth
50.20%6.10%
Total Constant Currency Growth
17.70%9.30%
Updated Dec 31, 2025. Data Source: Fiscal.ai.